Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Conference paper
    Hughes D, Rowley J, Elborn J, Armstrong-James D, Davies JCet al., 2019,

    SPYING ON INTER-SPECIES WARFARE: COMPLEX INTERACTIONS BETWEEN <i>PSEUDOMONAS</i> AND <i>ASPERGILLUS</i>

    , Publisher: WILEY, Pages: S306-S306, ISSN: 8755-6863
  • Journal article
    Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, Fiordoliva I, Newsom-Davis Tet al., 2019,

    Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer.

    , Ann Transl Med, Vol: 7, ISSN: 2305-5839

    BACKGROUND: Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). METHODS: We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) vs. SII <1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses. RESULTS: At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P<0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII >1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS. CONCLUSIONS: Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.
  • Conference paper
    Abu-Sbeih H, Faleck D, Ricciuti B, Mendelsohn R, Naqash AR, Cohen J, Sellers M, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad M, Leonardi G, Johnson D, Pinato D, Owen D, Weiss S, Lamberti G, Lythgoe M, Manuzzi L, Arnold C, Naidoo J, Merkel G, Powell N, Yeung S-C, Sharon E, Dougan M, Wang Yet al., 2019,

    Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

    , Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S451-S451, ISSN: 0002-9270
  • Conference paper
    Fischer A, Distler O, Khanna D, Allanore Y, Hoffmann-Vold AM, Valentini G, Maher T, Aringer M, Meng L, Alves M, Gahlemann M, Quaresma M, Kuwana Met al., 2019,

    Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

    , Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP), Publisher: WILEY, ISSN: 2326-5191
  • Conference paper
    Allanore Y, Khanna D, Volkmann E, Stock C, Gahlemann M, Schoof N, Distler O, Maher Tet al., 2019,

    Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences

    , Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP), Publisher: WILEY, ISSN: 2326-5191
  • Conference paper
    Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Distler Oet al., 2019,

    Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis

    , Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP), Publisher: WILEY, ISSN: 2326-5191
  • Conference paper
    Kreuter M, Hoffmnn-Vold AM, Matucci-Cerinic M, Saketkoo L, Highland K, Wilson H, Alves M, Schoof N, Maher Tet al., 2019,

    Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial

    , Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP), Publisher: WILEY, ISSN: 2326-5191
  • Conference paper
    Roofeh D, Brown K, Tashkin D, Assassi S, Barratt S, Bernstein E, Bhatt N, Chung L, Collard H, Conway R, Dellaripa P, Denton C, Distler O, Domsic R, Doyle TJ, Garcha P, Gupta N, Hoffmann-Vold AM, Hsu V, Ingegnoli F, Johannson K, Kahaleh B, Kawano-Dourado L, Kazerooni E, Khanna S, Korsten P, Lin CJF, Maher T, Mathai S, Martinez F, Matteson E, Nagaraja V, Oddis C, Ovalles-Bonilla J, Pauling J, Raghu G, Rodriguez-Pinto I, Rosas I, Seibold J, Steen V, Strand V, Volkmann E, Vummidi D, Walsh S, Zoz D, Wells A, Khanna Det al., 2019,

    Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions

    , Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP), Publisher: WILEY, ISSN: 2326-5191
  • Journal article
    Gleeson S, Willicombe M, Agarwal N, Wilson H, Lightstone Let al., 2019,

    COMPARISON OF ALEMTUZUMAB AND IL2 MONOCLONAL ANTIBODY INDUCTION IN TRANSPLANT RECIPIENTS WITH LUPUS NEPHRITIS

    , TRANSPLANT INTERNATIONAL, Vol: 32, Pages: 250-251, ISSN: 0934-0874
  • Conference paper
    Babalis D, Saglani S, Cornelius V, 2019,

    To fund or not to fund a paediatric severe asthma trial: that is the question

    , Publisher: BMC

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=1208&limit=10&resgrpMemberPubs=true&page=679&resgrpMemberPubs=true&respub-action=search.html Current Millis: 1778182291506 Current Time: Thu May 07 20:31:31 BST 2026